Brief: Polynoma Receives FDA Fast Track Designation For Its Melanoma Cancer Vaccine Seviprotimut-L
June 23 (Reuters) - CK Life Sciences Intl (Holdings) Inc
0775.HK :
* POLYNOMA RECEIVES FDA FAST TRACK DESIGNATION FOR ITS
MELANOMA
CANCER VACCINE SEVIPROTIMUT-L
Source text for Eikon: ID:nPn1kQjhDa
Further company coverage: 0775.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CK Life Sciences Intl (Holdings)
See all newsCK Life Sciences H1 loss narrows on lower R&D costs
Brief: CK Life Sciences Intl Announces Resignation Of Lance Richard Lee Yuen As Executive Director, CEO
Brief: CK Life Sciences Intl Logs FY Loss Attributable HK$186.8 Mln
CK Life Sciences rises most in 4 months on advancing cancer vaccine development
Brief: CK Life Sciences Intl Establishes Sequencio Therapeutics For Cancer Vaccine Development